Capricor Therapeutics Faces Investor Fraud Investigations Following Severe Stock Crash

2026-08-03 companies

New York, Sunday, 2 August 2026.
Law firms are investigating Capricor Therapeutics for potential securities fraud after undisclosed trial plan changes triggered a 64% stock crash following an adverse FDA efficacy report.

Multiple Law Firms Launch Securities Investigations

On August 2, 2026, The Rosen Law Firm announced a securities fraud investigation into Capricor Therapeutics, Inc. (NASDAQ: CAPR), focusing on potential misleading business disclosures that may have caused investor losses [1]. This action follows similar probes initiated by Hagens Berman, Block & Leviton, and Holzer & Holzer, signaling heightened scrutiny over the biotechnology firm’s regulatory communications [2][3][4]. The investigations center on whether the company violated federal securities laws by failing to accurately disclose risks associated with its experimental therapy, deramiocel [1]. Collectively, these legal actions underscore the severe market reaction to regulatory setbacks in the micro-cap biotechnology sector [1][4].

FDA Briefing Triggers Market Volatility

The catalyst for the investigations was a July 27, 2026, FDA briefing document which stated that Capricor’s Phase 3 HOPE-3 study failed to meet pre-specified primary and secondary efficacy endpoints [2]. Following this disclosure, Capricor shares fell approximately 64% to close at $7.00 on the same day, erasing significant value gained after positive topline results were announced in December 2025 [2][7]. The FDA noted that changes were made to the pre-specified Statistical Analysis Plan (SAP), including modifications to endpoint definitions and data imputation methods, raising questions about data integrity [2]. In contrast, the company had previously raised capital through a public offering of 6 million shares at $25 per share, valued at 150.000 million [2].

Advisory Committee and Regulatory Outlook

An FDA advisory committee meeting convened on July 29, 2026, to discuss the risk-benefit profile of deramiocel for Duchenne muscular dystrophy-related cardiomyopathy [1]. On July 30, 2026, the committee voted 3 against 9, with 12 total votes cast, indicating that available evidence did not support the effectiveness of the treatment [5]. Despite the non-binding negative vote, Capricor Therapeutics remains focused on working with the FDA toward potential approval before the PDUFA target action date of August 22, 2026 [5]. Investors and stakeholders await the final regulatory decision, which will determine the commercial viability of the therapy [5].

Sources

Securities Litigation Biotech Investments